ON APRIL 17, 2019, THE HOUSE ADOPTED AMENDMENT #1 AND PASSED HOUSE BILL 656, AS AMENDED. AMENDMENT #1 rewrites this bill. Under present law, only licensed physicians are authorized to prescribe any buprenorphine product for any federal food and drug administration approved use in recovery or medication-assisted treatment. Other healthcare providers who are otherwise permitted to prescribe Schedule II or Ill drugs are prohibited from prescribing any buprenorphine product for treatment of opioid dependence, but may participate in the assessment and management of patients with an opiate addiction. This amendment revises the above provisions to authorize non-physician healthcare providers who are otherwise permitted to prescribe Schedule II or III drugs to also prescribe a buprenorphine product for the treatment of opioid use disorder if the healthcare provider: (A) Is licensed and has practiced as a family, adult, or psychiatric nurse practitioner or physician assistant in this state; (B) Has had no limitations or conditions imposed on the provider's license by the provider's licensing authority within the previous three years; (C) Is employed by a community mental health center or a federally qualified health center that employs one or more physicians and has adopted clinical protocols for medication-assisted treatment; (D) Works under the supervision of a physician who holds a waiver registration from the federal drug enforcement agency that authorizes the physician to prescribe buprenorphine products; (E) Obtains a waiver registration from the federal drug enforcement agency that authorizes the provider to prescribe buprenorphine products under federal law; (F) Prescribes buprenorphine products only to patients who are treated through the organization that employs the provider; and (G) Writes prescriptions that can only be dispensed by a licensed pharmacy to ensure entry into the controlled substance database.